Organogenesis Holdings Inc.

NasdaqCM:ORGO Stock Report

Market Cap: US$415.0m

Organogenesis Holdings Future Growth

Future criteria checks 3/6

Organogenesis Holdings is forecast to grow earnings and revenue by 123.4% and 4.6% per annum respectively. EPS is expected to grow by 122.5% per annum. Return on equity is forecast to be 1.2% in 3 years.

Key information

123.4%

Earnings growth rate

122.5%

EPS growth rate

Biotechs earnings growth26.7%
Revenue growth rate4.6%
Future return on equity1.2%
Analyst coverage

Low

Last updated12 Dec 2024

Recent future growth updates

Recent updates

Organogenesis: Lurking Disruption With Recovery To Follow

Oct 15

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Sep 09
Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

NasdaqCM:ORGO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202651113N/AN/A3
12/31/20254732N/AN/A4
12/31/2024466-9N/AN/A4
9/30/2024455-7414N/A
6/30/2024448-17922N/A
3/31/20244356726N/A
12/31/20234335731N/A
9/30/202344913-428N/A
6/30/202345710-1917N/A
3/31/202346113-1618N/A
12/31/202245116-925N/A
9/30/202246359735N/A
6/30/2022460712357N/A
3/31/2022462833265N/A
12/31/2021467943162N/A
9/30/2021446623667N/A
6/30/2021433692848N/A
3/31/202137943321N/A
12/31/202033817-125N/A
9/30/2020306-5-40-24N/A
6/30/2020270-37-50-38N/A
3/31/2020266-42-51-41N/A
12/31/2019261-39-40-34N/A
9/30/2019250-46-48-45N/A
6/30/2019236-48-65-62N/A
3/31/2019215-58-68-66N/A
12/31/2018193-65-62-61N/A
9/30/2018183-60-48-46N/A
6/30/2018184-52N/A-25N/A
3/31/2018187-32N/A-9N/A
12/31/2017199-9N/A-3N/A
12/31/2016139-17N/A-5N/A
12/31/201599-24N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORGO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: ORGO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ORGO is expected to become profitable in the next 3 years.

Revenue vs Market: ORGO's revenue (4.6% per year) is forecast to grow slower than the US market (9% per year).

High Growth Revenue: ORGO's revenue (4.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ORGO's Return on Equity is forecast to be low in 3 years time (1.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:12
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Organogenesis Holdings Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
Ross OsbornCantor Fitzgerald & Co.
Matthew MiksicCredit Suisse